Crotalid venom vascular endothelial growth factors has preferential affinity for VEGFR-I

Thrombosis and Haemostasis

Volumn 93, Issue 2, 2005, Pages 331-338

  Chen, Yuh Ling ^a,b   Tsai, Inn Ho ^a,e   Hong, Tse Ming ^c   Tsai, Shu Huei ^d  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NONE   (Taiwan)

Author keywords

Angiogenesis; Monocyte chemotaxis; Receptor specificity; Snake venom VEGF; Vascular permeability

Indexed keywords

NEUROPILIN 1; SNAKE VENOM; THROMBOPLASTIN; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AMINO ACID SEQUENCE; ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; COMPARATIVE STUDY; ENDOTHELIUM CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TAIWAN;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CLONING, MOLECULAR; CROTALID VENOMS; ENDOTHELIUM, VASCULAR; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; SEQUENCE ALIGNMENT; SURFACE PLASMON RESONANCE; THROMBOPLASTIN; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 13844267683     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-09-0568     Document Type: Article

References (45)

1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
2. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-43.
4. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
5. Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects ofvascular endothelial cell growth factor. Int J Hematol 1995; 62: 203-15.
6. Gerber HP, Malik AK, Solar GF, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-8.
7. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
8. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.
9. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
10. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35.
11. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6.
12. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
13. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 2000; 26: 561-9.
14. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-54.
15. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
16. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-40.
17. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002; 8: 841-9.
18. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-65.
19. Lange T, Guttmann-Raviv N, Baruch L, et al. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J Biol Chem 2003; 278: 17164-9.
20. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-7.
21. Olofsson B, Pajusola K, von Euler G, et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 1996; 271: 19310-7.
22. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-8.
23. Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001; 33: 421-6.
24. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18: 363-74.
25. Komori Y, Sugihara H. (1990) Purification and physiological study of a hypotensive factor from the venom of Vipera aspis aspis (aspic viper). Toxicon 1990; 28: 359-69.
26. Komori Y, Nikai T, Taniguchi K, et al. Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper). Biochemistry 1999; 38: 11769-803.
27. Gasmi A, Abidi F, Srairi N, et al. Purification and characterization of a growth factor-like which increases capillary permeability from Vipera lebetina venom. Biochem Biophys Res Commun 2000; 268: 69-72.
28. Gasmi A, Bourcier C, Aloui Z, et al. (2002) Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. J Biol Chem 2002; 277: 29992-8.
29. Junqueira de Azevedo IL, Farsky SH, et al. Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. J Biol Chem 2001; 276: 39836-42.
30. 2 from the venom of Taiwan habu (Trimeresurus mucrosquamatus). Biochem J 1995; 311: 895-900.
31. Sozzani SW, Luini W, Molino M, et al. The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol 1991; 147: 2215-21.
32. McDonald NQ, Hendrickson WA. A structural superfamily ofgrowth factors containing a cystine knot motif. Cell 1993; 73: 421-4.
33. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.
34. Miles AA, Wilhelm DL. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. I. An activable permeability factor and its inhibitor in guinea-pig serum. Br J Exp Pathol 1955; 36: 71-81.
35. Schratzberger P, Kahler CM, Wiedermann CJ. (1996) Use of fluorochromes in the determination of chemotaxis and haptotaxis of granulocytes by micropore filter assays. Ann Hematol 1996; 72: 23-7.
36. Takahashi H, Hattori S, Iwamatsu A, et al. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J Biol Chem 2004; 279: 46304-14.
37. Scrofani SD, Fabri LJ, Xu P, et al. Purification and refolding of vascular endothelial growth factor-B. Protein Sci 2000; 9: 2018-25.
38. Siemeister G, Schnurr B, Mohrs K, et al. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. BBRC 1996; 222: 249-55.
39. Hung CC, Chiou, SH. Fibrinogenolytic proteases isolated from the snake venom of Taiwan habu: serine proteases with kallikrein-like and angiotensin-degrading activities. Biochem. Biophys Res Commun 2001; 281: 1012-8.
40. 2 homolog from the venom of Trimeresurus mucrosquamatus. Biochim Biophys Acta, 1991; 1077: 362-70.
41. Yamazaki Y, Takani K, Atoda H, et al. Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J Biol Chem 2003; 278: 51985-8.
42. Wiesmann C, Fuh G, Christinger HW, et al. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91: 695-704.
43. Muller YA, Li B, Christinger HW, et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997; 94: 7192-7.
44. Li B, Fuh G, Meng G, et al. Receptor-selective variants of human vascular endothelial growth factor: generation and characterization. J Biol Chem 2000; 275: 29823-8.
45. Higgins D, Thompson J, Gibson T, et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.